DavidM.HuffmanMDMS,FACE

Endocrinology • Chattanooga, TN

Diabetes, Lipid Metabolism

Head, University Diabetes & Endocrine Consultants

Join to view full profile

Dr. Huffman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Huffman's full profile

Already have an account?

Office
5616 Brainerd Rd
Ste 208
Chattanooga, TN 37411
Phone+1 423-265-3561

Fax+1 423-265-1364
Is this information wrong?

Education & Training

Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 1986 - 1989
Baylor College of MedicineResidency, Internal Medicine, 1983 - 1986
University of North Carolina at Chapel Hill School of MedicineClass of 1982

Certifications & Licensure

TN State Medical License 1989 - 2026
NC State Medical License 1984 - 2025
TX State Medical License 1988 - 1991
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Fellow (FACE) American Association of Clinical Endocrinology

Clinical Trials

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes Start of enrollment: 2007 Jul 01
Completed
Phase 4
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting Start of enrollment: 2012 Jan 01
Completed
OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits Start of enrollment: 2014 Mar 17
Completed
Not Applicable
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data Start of enrollment: 2013 Nov 26
Completed
Not Applicable
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2014 Apr 01
Terminated
Phase 2
Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients Start of enrollment: 2015 Aug 01
Completed
Not Applicable
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2015 Oct 20
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 di...
Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patr...> ;Diabetes, Obesity & Metabolism. 2024 Jun 1
29 citations
Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossov...
Matthew C. Riddle, Rajaa Nahra, Jenny Han, Jessica R. Castle, Kathryn Hanavan, Marcus Hompesch, David Huffman, Poul Strange, Peter Öhman> ;Diabetes Care. 2018 Sep 12
16 citations
Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study.
David M. Huffman, George W. McLean, Maighan A. Seagrove> ;Endocrine Practice. 2009 Nov 1

Press Mentions

Glucokinase Mutation-A Rare Cause of Recurrent Hypoglycemia in Adults: A Case Report and Literature ReviewOctober 26th, 2016

Hospital Affiliations

CHI MemorialChattanooga, Tennessee